KHC
PMCB icon

Koesten Hirschmann & Crabtree’s PharmaCyte Biotech PMCB Stock Holding History

Koesten Hirschmann & Crabtree’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$2 – 345
2025
Q2 		$2 Buy
+1
New +$1 ﹤0.01% 345

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Koesten Hirschmann & Crabtree's PMCB Position: Q3 2025 in Review

Koesten Hirschmann & Crabtree sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 1 share — an estimated $2 sold.

Koesten Hirschmann & Crabtree first reported a position in PMCB in Q2 2025 and held it in 1 quarter. The position peaked at $2 in Q2 2025. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

  • Koesten Hirschmann & Crabtree reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
  • Koesten Hirschmann & Crabtree sold 1 PharmaCyte Biotech share in Q3 2025, an estimated $2.
  • Koesten Hirschmann & Crabtree first reported a position in PharmaCyte Biotech in Q2 2025 and held it in 1 quarter.
  • Koesten Hirschmann & Crabtree's PharmaCyte Biotech position peaked at $2 in Q2 2025.
  • 23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Koesten Hirschmann & Crabtree's 13F filing for Q3 2025, filed 5 Nov 2025.